Methicillin-Resistant Staphylococcus Aureus (MRSA): Difference between revisions

No edit summary
(No difference)

Revision as of 08:02, 4 March 2014

Background

Suspect MRSA infection/carrier in patients who present with:

  1. multiple skin sites
  2. recurrent infection
  3. pt who has been in close contact of person with Hx of MRSA
  4. infection showing early necrosis
  5. two kinds: hospital acquired and community acquired
    1. Hospital acquired tends to be multi-drug resistant, most commonly seen in ventilator associated pneumonia, post operative infections, and catheter associated infections
    2. Community acquired tends to be resistant to beta-lactams, most commonly seen in soft tissue infections and rarely in necrotizing pneumonia

Prevention

  1. good hand hygiene
  2. avoid sharing personal items with carriers
  3. wash common household items with bleach and hot water
  4. wash soiled sheets, towels, clothes in hot water with bleach and dry in hot dryer
  5. Eradicate carriers:
  6. mupirocin 2%: apply to each nostril TID x 5days
  7. Hibiclens wash daily x 5 days
  8. consider oral antibiotics

Treatment

  1. Antibiotics
    1. Cephalexin + Bactrim DS
      1. Estimated 95-100% sensitivity of CA-MRSA
    2. Clindamycin
      1. Approximately 50% sensitivity to CA-MRSA
      2. Inducible resistance by erythromycin in laboratory, unclear significance
    3. doxycycline
      1. Contraindicated in pregnant females and children due to deposition in teeth and bones
    4. Vancomycin IV if severe infection/sepsis
    5. Linezolid
      1. Indicated in severe soft tissue infections and pneumonia thought to be caused by CA-MRSA or HA-MRSA
  2. I&D if abscess
    1. (antibiotics not needed if no e/o cellulitis)

Antibiotic Sensitivities[1]

Organisms ' Staph. aureus (MRSA)
Penicillins Penicillin G 0
Penicillin V 0
Anti-Staphylocccal Penicillins Methicillin 0
Nafcillin/Oxacillin 0
Cloxacillin/Diclox. 0
Amino-Penicillins AMP/Amox 0
Amox/Clav 0
AMP-Sulb 0
Anti-Pseudomonal Penicillins Ticarcillin 0
Ticar-Clav 0
Pip-Taxo 0
Carbapenems Piperacillin 0
Doripenem 0
Ertapenem 0
Imipenem 0
Meropenem 0
Aztreonam 0
Fluroquinolones Ciprofloxacin 0
Ofloxacin 0
Pefloxacin 0
Levofloxacin 0
Moxifloxacin +/-
Gemifloxacin +/-
Gatifloxacin +/-
1st G Cephalosporin Cefazolin 0
2nd G. Cephalosporin Cefotetan 0
Cefoxitin 0
Cefuroxime 0
3rd/4th G. Cephalosporin CefoTAXime 0
Cefizoxime 0
CefTRIAXone 0
Ceftobiprole +
Ceftaroline +
CefTAZidime 0
Cefepime 0
Oral 1st G. Cephalosporin Cefadroxil 0
Cephalexin 0
Oral 2nd G. Cephalosporin Cefaclor/Loracarbef 0
Cefproxil 0
Cefuroxime axetil 0
Oral 3rd G. Cephalosporin Cefixime 0
Ceftibuten 0
Cefpodox/Cefdinir/Cefditoren 0
Aminoglycosides Gentamicin 0
Tobramycin 0
Amikacin 0
Chloramphenicol 0
Clindamycin 0
Macrolides Erythromycin 0
Azithromycin 0
Clarithromycin 0
Ketolide Telithromycin 0
Tetracyclines Doxycycline +/-
Minocycline +/-
Glycylcycline Tigecycline +
Glyco/Lipoclycopeptides Vancomycin +
Teicoplanin +
Telavancin +
Fusidic Acid +
Trimethoprim +/-
TMP-SMX +
Urinary Agents Nitrofurantoin +
Fosfomycin
Other Rifampin +
Metronidazole 0
Quinupristin dalfoppristin +
Linezolid +
Daptomycin +
Colistimethate 0

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

Table Overview

See Also

Source

  • EBmedicine.net

References

  1. Sanford Guide to Antimicrobial Therapy 2010